fda compounding glp-1 BREAKING NEWS in the space 🚨 , is at it again saying they’re going to take action limiting access to the active ingredients used to make the compounded medications. , Watch this FDA to Restrict Ingredients Used

Akkermansia muciniphila treatment improves host metabolism Insulin resistance and metabolic syndrome are the most prominent characteristics of T2D, and A

Presented for research literature review only Cassone VM et al

You pay four times more for a hundredth of the dose in a delivery format that has never been shown to achieve systemic blood levels

The medication was effective but required reconstitution before each injection, which patients found inconvenient

Whether it is decided to initially decrease the dose or hold the background sulfonylurea altogether, continued use and titration of the sulfonylurea should be informed by patient response and BGM data

Gastrointestinal effects are the most common